MM patients treated with anti‐CD38 agents are at higher risk of infectious complications, especially pneumonia not Varicella‐Zoster Virus‐related, without an associated higher mortality rate.12 This evidence concerns the gene CD38 and susceptibility to pneumonia measurement.